captodiamine退出长期作用的苯二氮卓类药物治疗。

文章的细节

引用

复制到剪贴板

Mercier-Guyon C, Chabannes JP, Saviuc P

captodiamine退出长期作用的苯二氮卓类药物治疗。

咕咕叫地中海Res当今。2004年9月,20 (9):1347 - 55。

PubMed ID

15383182 (在PubMed

]

文摘

背景和目的:停药可以与苯二氮卓类戒断综合症的出现妥协成功终止治疗。本研究的目的是评估是否六周期间政府captodiamine苯二氮卓类药物停药可以防止苯二氮卓类药物戒断综合征的出现,从而促进这些药物的停用。对象和方法:对照、随机、双盲试验captodiamine和安慰剂进行治疗的81例呈现轻度至中度焦虑和至少6个月稳定剂量的苯二氮卓类药物。每个主题逐渐断奶的苯二氮卓类在14天内使用逐渐减少剂量的时间表和接收captodiamine (150 mg / d)或安慰剂的45天断奶期的开始。结果测量:主要结果则是戒断症状的严重程度评估使用轮胎的苯二氮卓类药物戒断症状问卷。二次结果标准;自我评价的紧张、焦虑、困倦和减缓身心性能使用视觉模拟尺度;使用明镜问卷的睡眠质量;使用汉密尔顿焦虑量表焦虑;使用驾驶刺激试验和认知功能。 RESULTS: Analysis of the primary study criterion revealed a statistically significant difference (p < 0.0001) in the emergence of withdrawal symptoms between the two groups in favour of captodiamine at two, six and eight weeks following initiation of therapy. These results were supported by significant beneficial effects of captodiamine on the majority of secondary outcome measures. The switch to captodiamine was associated with an improvement in vigilance, which may be an advantage for the overall safety of the anxiolytic treatment, for example with regard to road safety. Discontinuation of captodiamine was not associated with the emergence of rebound anxiety. CONCLUSION: Captodiamine represents an interesting strategy for achieving benzodiazepine substitution with a low risk of dependence or impairment of cognitive function. Further clinical studies addressing the anxiolytic activity and safety of captodiamine in such subjects are merited.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Captodiame